An updated review on prediction and preventive treatment of post-stroke depression

Sun, Shuai; Li, Zhifang; Xiao, Qing; Tan, Senwei; Hu, Bo; Jin, Huijuan

doi:10.1080/14737175.2023.2234081

Cited by 3 publications

(1 citation statement)

References 170 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conversely, a stroke could also trigger and exacerbate symptoms of depression and anxiety ( Chen et al, 2023 ). Early identification and prevention of post-stroke depression (PSD) can significantly improve patients’ depressive symptoms, promote the recovery of physical and cognitive functions, and thereby enhance the prognosis of stroke and the 10-year survival rate ( Robinson and Jorge, 2016 ; Sun et al, 2023 ). It was reported that, in middle cerebral artery occlusion (MCAO) and chronic CUMS model rats, a single local injection of ketamine in the dentate gyrus region could enhance synaptic plasticity by regulating NMDAR/calcium/calcium-calmodulin-dependent protein kinase II (CaMKII), thereby producing significant and long-lasting antidepressant effects ( Abdoulaye et al, 2021 ).…”

Section: Research On Non-depressive Conditionsmentioning

confidence: 99%

Exploring the multifaceted potential of (R)-ketamine beyond antidepressant applications

Zhang,

Pu,

Liu

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

(R, S)- and (S)-ketamine have made significant progress in the treatment of treatment-resistant depression (TRD) and have become a research focus in recent years. However, they both have risks of psychomimetic effects, dissociative effects, and abuse liability, which limit their clinical use. Recent preclinical and clinical studies have shown that (R)-ketamine has a more efficient and lasting antidepressant effect with fewer side effects compared to (R, S)- and (S)-ketamine. However, a recent small-sample randomized controlled trial found that although (R)-ketamine has a lower incidence of adverse reactions in adult TRD treatment, its antidepressant efficacy is not superior to the placebo group, indicating its antidepressant advantage still needs further verification and clarification. Moreover, an increasing body of research suggests that (R)-ketamine might also have significant applications in the prevention and treatment of medical fields or diseases such as cognitive disorders, perioperative anesthesia, ischemic stroke, Parkinson’s disease, multiple sclerosis, osteoporosis, substance use disorders, inflammatory diseases, COVID-19, and organophosphate poisoning. This article briefly reviews the mechanism of action and research on antidepressants related to (R)-ketamine, fully revealing its application potential and development prospects, and providing some references and assistance for subsequent expanded research.

show abstract

Section: Research On Non-depressive Conditionsmentioning

confidence: 99%

Exploring the multifaceted potential of (R)-ketamine beyond antidepressant applications

Zhang,

Pu,

Liu

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

Development, validation, and visualization of a novel nomogram to predict depression risk in patients with stroke

Wu,

Zhu,

Wang

et al. 2024

Journal of Affective Disorders

View full text Add to dashboard Cite

Correlation of Circadian Rhythms and Improvement of Depressive Symptoms in Acute Ischemic Stroke Patients

Ding,

Chen,

Sun

et al. 2024

CNR

View full text Add to dashboard Cite

Objectives:: To investigate the correlation between evening melatonin timing secretion, dim light melatonin onset (DLMO), and post-stroke depression (PSD) in acute ischemic stroke (AIS) patients and their influence on the improvement of depressive symptoms. Materials and Methods:: 120 patients with a recent magnetic resonance imaging confirmed stroke were included. Salivary melatonin samples were collected at 5 time points within 1 week after hospitalization (7 p.m.-11 p.m., 1 sample per hour). The circadian phase was defined by calculating DLMO secretion. Post-stroke depressive symptoms were evaluated by the 17-item Hamilton Rating Scale for Depression (HRSD) both on day 7 of hospitalization and 3 months after stroke. Patients were divided into PSD and non-PSD groups based on whether the acute phase HRSD score was ≥8. Similarly, patients were divided into the improved depressive symptoms (IDS) and no improvement in depressive symptoms (non-IDS) groups based on whether the HRSD score at 3 months was lower than at baseline. Neurological recovery at 3 months was assessed using the modified Rankin Scale (mRS). Results:: The difference in DLMO between PSD and non-PSD patients was not statistically significant (p =0.173). In the non-IDS group, there was a significant decrease in melatonin secretion at 10 p.m. (p =0.012), and DLMO was significantly later than in the IDS group (p =0.017). Logistic regression analysis showed that DLMO (OR 1.91, 95%CI:1.13-3.23, p = 0.016) was an independent risk factor for persistent no improvement in depressive symptoms, which was associated with a markedly worse prognosis (p <0.001). Conclusion:: Our findings suggest possible interventions for the very early identification of non- IDS patients.

show abstract

An updated review on prediction and preventive treatment of post-stroke depression

Cited by 3 publications

References 170 publications

Exploring the multifaceted potential of (R)-ketamine beyond antidepressant applications

Exploring the multifaceted potential of (R)-ketamine beyond antidepressant applications

Development, validation, and visualization of a novel nomogram to predict depression risk in patients with stroke

Correlation of Circadian Rhythms and Improvement of Depressive Symptoms in Acute Ischemic Stroke Patients

Contact Info

Product

Resources

About